Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190606 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
A Phase 2 study of Urinary Stress Incontinence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00190606: Completed Phase 2 study of Urinary Stress Incontinence, sponsored by Eli Lilly and Company.
NCT00190606 is a Phase 2 study of Urinary Stress Incontinence that has completed, run by Eli Lilly and Company. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00190606, a Phase 2 study of Urinary Stress Incontinence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG placebo
- PROCEDURE Pelvic Floor Muscle Training (PFMT)
- PROCEDURE Imitation PFMT
Study Locations (2)
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Weston
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician - Nieuwegein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00190606 record still lists
NCT00190606 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Urinary Stress Incontinence appearing as the primary indexed condition, and to 4 interventions - of which Duloxetine is the first listed.
NCT00190606 reports a single indexed study location in Florida, Other.
Frequently Asked Questions
What is clinical trial NCT00190606 about?
NCT00190606 is a clinical study titled "Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence". The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence
What is the current status of trial NCT00190606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2002-01. Estimated completion is 2006-04.
What conditions does trial NCT00190606 study?
This clinical trial studies the following conditions: Urinary Stress Incontinence.
What interventions are being tested in trial NCT00190606?
The interventions under investigation include: Duloxetine (DRUG), placebo (DRUG), Pelvic Floor Muscle Training (PFMT) (PROCEDURE), Imitation PFMT (PROCEDURE).
Who is sponsoring clinical trial NCT00190606?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190606 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00190606's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia